Dimethyl sulfoxide favors the emetic efficacy of lycorine in beagle dogs - a novel strategy for the treatment of poisoning.

Res Vet Sci. July 2023;160(0):11 - 17.

Ralf Regenthal¹, Getu Abraham²

¹ Division of Clinical Pharmacology, Rudolf Boehm Institute for Pharmacology and Toxicology, Medical Faculty, University of Leipzig, Härtelstrasse 16-18, 04107 Leipzig, Germany. Electronic address: ralf.regenthal@medizin.uni-leipzig.de.; ² Institute of Pharmacology, Pharmacy and Toxicology, Faculty of Veterinary Medicine, University of Leipzig, An den Tierkliniken 15, 04103 Leipzig, Germany.

Abstract

Poisoning in small animals represents an ongoing hazard and therapeutic problem in veterinary medicine. Therapeutic induction of emesis in time enables a fast elimination of a toxic compound resulting in a shortened course of poisoning and a higher safety level thereafter, which decisively improves prognosis and treatment. Lycorine is a reliable emetic drug in beagle dogs without serious side effects thought to be more beneficial in tolerability and efficacy than the rarely used apomorphine. Therefore, this study investigates efficacy and tolerability of differently composed potential drug formulations of lycorine hydrochloride for s.c. administration in dogs as an emetic principle. By emesis response analysis four dimethyl sulfoxide (DMSO)-based active pharmaceutical ingredient (API) formulations were favored. Two of them (F5 and F6) qualified for further drug development. Both formulations ensure a safe pharmacologically induced emesis within about 30 min after injection, suitable for use as an in time decontaminant in acute poisoning of dogs. DMSO-based formulations were well tolerated and offer a novel promising strategy for treatment of poisoning.

Keywords

Dog; Drug formulation; Emetic drug; Lycorine; Poisoning;

Article Tools:

Medline

Email to me

Archives Highlights:

'Transmission Tracker - Dirofilaria'- a public dashboard to assess in real-time the temperature-bounded transmissibility of canine heartworm across Australia.
'Transmission Tracker - Dirofilaria' processes near real-time temperature records across Australia and allows users to enquire about historical and current weather suitability for canine heartworm transmission at any Australian postcode of their interest. This information allows veterinarians to access when, and for how long, heartworm may be transmitted at a specific location, assess the associated risk of infection, and advise on a patient-dependent dirofilariosis prevention plan for their canine patients and guardians.

Investigation of maternal mortality and stillbirth in feline dystocia after emergency obstetric care interventions: a retrospective analysis.
Medical treatment was successful in 17% of patients, and 83% underwent surgical treatment for dystocia. Ovariohysterectomy (59%) was the most common surgical method, followed by conservative caesarean section (35%).

Efficacy, safety and interval from end of treatment to estrus in cats treated with an ultra-low dose megestrol acetate protocol for suppression of reproductive activity.
Twenty-eight queens were treated orally with 11.5 µg/kg/day of megestrol acetate (MA) for one to six months. MA suppressed reproductive function effectively in 27/28 queens. Transient mammary and uterine hyperplasia were detected in four (14 %) and three (11 %) queens, respectively, treated for more than four months, without associated clinical signs. Significant but reversible weight gain was observed in 85 % of the animals. The resumption of cyclicity occurred on average 6 weeks after the end of treatment but was influenced by the duration of treatment and seasonality.

Retrospective cohort study on diseases and risk factors associated with death in hospitalized neonatal foals.
Most prevalent diseases were sepsis (43.9%), enteritis (14.0%), and omphalitis (9.0%). Case fatality rate was 33.3%. Neonatal sepsis significantly increased the risk of death.

Effective treatment with afoxolaner (NexGard) of Trixacarus caviae in a pet guinea pig.
The animal was treated with a single oral dose of 2.50 mg/kg afoxolaner, and the lesions, presence/absence of mites, and intensity of pruritus were evaluated periodically until 2 months post-treatment. A week after the medication, the lesions were milder, but pruritus was still present and was attributed to the healing process. Further examinations showed significant improvement with the complete remission of clinical signs and no mites at the microscopic examination after 4 weeks.